Erotomania induced by venlafaxine: A case study

Acta Psychiatrica Scandinavica

Volumn 107, Issue 4, 2003, Pages 314-317

  Adamou, Marios ^a   Hale, A S ^b  

^a KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Antidepressants; Depressive disorder; Dopamine; Erotomania

Indexed keywords

VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; EROTOMANIA; FEMALE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; CYCLOHEXANOLS; DELUSIONS; DEPRESSIVE DISORDER; FEMALE; HUMANS; LOVE;

EID: 0037393208     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2003.00055_1.x     Document Type: Article

References (31)

1. MCEWAN I. Enduring Love. London: Vintage, 1988.
2. DECLERAMBAULT G. Les psychoses pasionelles. Oeuvre psychiatrique. Paris: Presses de France, 1942.
3. REMINGTON G. Case report of de Clerembault syndrome, bipolar affective disorder, and response to lithium. Am J Psychiatry 1984;141:1285-1287.
4. EVANS DL. Erotomania. A variant of pathological mourning. Bull Menninger Clinic 1982;46:507-520.
5. DREVETS WC. Erotomania and senile dementia of Alzheimer type. Br J Psychiatry 1987;151:400-402.
6. DOUST JW. The pathology of love: some clinical variants of De Clerambault's syndrome. Social Sci Med 1978;12:99-106.
7. MAZEH D, MERIMSKY O, MELAMED Y et al. Erotomania following an orchiectomy: a case report. J Sex Marital Ther 1997;23:154-155.
8. American Psychiatric Association. Diagnostic Statistical Manual of Mental Disorders-IV-TR, 4th edn. Washington: American Psychiatric Association, 2000.
9. FIRST MB, SPITZER RLGM, WILLIAMS JBW. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Verion (SCID-CV). Washington DC: American Psychiatric Press, 1997.
10. MONTGOMERY SA, ASBERG M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
11. MCGUIRE BE. Somatic sexual hallucinations and erotomanic delusions in a mentally handicapped woman. J Intellect Disabil Res 1994;38:79-83.
12. KELLY BD. Delusion and desire: erotomania revisited. Acta Psychiatrica Scand 2000;102:74-75.
13. SCHILDKRAUT JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522.
14. WILLNER P. Depression. New York: John Wiley & Sons Inc, 1985.
15. LITTLE KY. Amphetamine, but not methylphenidate, predicts antidepressant efficacy. J Clin Psychopharmacol 1988;8:177-183.
16. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312:35-44.
17. BOURAS N, BRIDGES PK. Bromocriptine in depression. Curr Med Res Opin 1982;8:150-153.
18. MATTES JA. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Ann Clin Psychiatry 1997;9:87-88.
19. SPYRAKI C. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 1981;74:195-206.
20. MAJ J. The effect of repeated administration of imipramine, citalopram and mianserin on responsiveness of central serotonergic, alpha 2-adrenergic and cholinergic system in mice. Polish J Pharmacol Pharmacy 1989;41:313-319.
21. COLLU M. Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats. Eur J Pharmacol 1997;322:123-127.
22. D'AQUILA PS. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000;405:365-373.
23. WILLNER P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997;12(Suppl. 3):S7-S14.
24. MUSCAT R, PAPP M, WILLNER P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl) 1992;109:433-438.
25. SAMPSON D, WILLNER P, MUSCAT R. Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology (Berl) 1991;104:491-495.
26. MUTH EA, HASKINS JT, MOYER JA et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986;35:4493-4497.
27. MAJ J. Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J Neural Transm Gen Sect 1999;106:197-211.
28. WALDMEIER PC, MAITRE L. On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs. J Neurochem 1976;27:589-597.
29. GUPTA N. Venlafaxine-induced hypomanic switch in bipolar depression. Can J Psychiatry 2001;46:760-761.
30. BUNNEY WE JR., MURPHY DL, GOODWIN FK et al. The 'switch process' in manic-depressive illness. I. A systematic study of sequential behavioral changes. Arch Gen Psychiatry 1972;27:295-302.
31. RISCH SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy 1996;16(1 Part 2):11-14.